Work

Abstract PS5-08-11: Trial in Progress: Phase II Open-Label Study of ARX788 (anti-HER2 Antibody Drug Conjugate (ADC)) for Patients with HER2-Low Locally Advanced Unresectable or Metastatic Breast Cancer

Year: 2026

Type: conference-abstract

Source: Clinical Cancer Research

DOI: 10.1158/1557-3265.sabcs25-ps5-08-11

Authors: L. A. Huppert, N. D. Pasricha, K. Nathalie, C. Galia, J. Rossi, A. DeLuca, K. Natsuhara, H. Batra-Sharma, M. Majure, M. Melisko, J. Chien, H. Rugo

Institutions: University of California, San Francisco, City Of Hope National Medical Center, City of Hope

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7129598485

Cites:

Cited by:

Related to: